Macrolides have historically been used to fill a therapeutic gap in T2-low asthma, but the advent of tezepelumab—a Thymic Stromal Lymphopoietin (TSLP)-blocking biologic—has shifted this landscape. The gene discussed is TSLP; the disease is asthma.